Profil
Teresa Lama worked as a Senior Scientist-Medicinal Chemistry at Mimetogen Pharmaceuticals, Inc. from 2007 to 2015.
Prior to that, she worked as a Principal at Università degli Studi di Napoli Federico II.
Dr. Lama received a graduate and doctorate degree from Università degli Studi di Napoli Federico II.
Anciens postes connus de Teresa Lama
| Sociétés | Poste | Fin |
|---|---|---|
Mimetogen Pharmaceuticals, Inc.
 Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/09/2015 |
| Università degli Studi di Napoli Federico II | Corporate Officer/Principal | - |
Formation de Teresa Lama
| Università degli Studi di Napoli Federico II | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |